Hypera S.A. (HYPMY)
| Market Cap | 1.91B |
| Revenue (ttm) | 1.43B |
| Net Income (ttm) | 288.05M |
| Shares Out | n/a |
| EPS (ttm) | 0.45 |
| PE Ratio | 6.63 |
| Forward PE | n/a |
| Dividend | 0.15 (4.75%) |
| Ex-Dividend Date | Oct 4, 2024 |
| Volume | 2,100 |
| Open | 3.010 |
| Previous Close | 2.990 |
| Day's Range | 2.920 - 3.010 |
| 52-Week Range | 2.640 - 7.900 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 21, 2025 |
About Hypera
Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, pleased, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, Luna, moon, Lydian, macrodantin, MaxSulid, Milgamma, Mioflex – A, Nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, Softalm, Tacroz, Tinodin, Umma, an... [Read more]
Full Company ProfileFinancial Performance
In 2023, Hypera's revenue was 7.91 billion, an increase of 4.88% compared to the previous year's 7.55 billion. Earnings were 1.65 billion, a decrease of -2.87%.
Financial numbers in BRL Financial StatementsNews
Hypera: Short-Term Pain For Long-Term Gain
Hypera is a top pharmaceutical company in Brazil, dominating the OTC market with a strong brand portfolio. Overleveraged acquisitions, Brazil's slowing pharma market, and high interest rates have caus...
Hypera S.A.: Adding The Brazilian Pharma To Your Portfolio
In Reais, I believe there is a 30% upside on Hypera S.A. due to improving margins as the company increases its operation by acquiring other brands and internal development. 75% of the Sell-Side Analys...
A Brazilian-Focused Dividend Portfolio
Four out of thirty-seven Brazilian ADRs scored five out of five on the dividend binomial test and they have an equalweight average 2022 forward dividend yield of 7.6%.